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Abstract The evolutionary dynamics of cancerous cell
populations in a model of Chronic Myeloid Leukemia
(CML) is investigated in the presence of an intermittent
targeted therapy. Cancer development and progression is
modeled by simulating the stochastic evolution of initially
healthy cells which can experience genetic mutations and
modify their reproductive behavior, becoming leukemic
clones. Front line therapy for the treatment of patients
affected by CML is based on the administration of tyrosine
kinase inhibitors, namely imatinib (Gleevec) or, more
recently, dasatinib or nilotinib. Despite the fact that they
represent the first example of a successful molecular tar-
geted therapy, the development of resistance to these drugs
is observed in a proportion of patients, especially those in
advanced stages. In this study, we simulate an imatinib-like
treatment of CML by modifying the fitness and the death
rate of cancerous cells and describe the several scenarios in
the evolutionary dynamics of white blood cells as a con-
sequence of the efficacy of the different modeled therapies.
The patient response to the therapy is investigated by
simulating a drug administration following a continuous or
pulsed time scheduling. A permanent disappearance of
leukemic clones is achieved with a continuous therapy.
This theoretical behavior is in a good agreement with that
observed in previous clinical investigations. However,
these findings demonstrate that an intermittent therapy
could represent a valid alternative in patients with high risk
of toxicity. A suitable tuned pulsed therapy can also reduce
the probability of developing resistance.
Keywords Stochastic dynamics  Cancer evolution 
Complex systems
Introduction
Leukemia is a form of cancer of the blood cells. Healthy
white blood cells grow and divide in an orderly and con-
trolled way, but in leukemia the process gets out of control
and the cells divide too quickly. In Chronic Myeloid
Leukemia (CML), too many myeloid cells (one of the main
types of white blood cells) are produced and released into
the blood when they are immature and unable to work
properly, leading to an increased risk of infection and
strongly limiting the production of healthy red cells and
platelets. A specific chromosomal abnormality, named
Philadelphia (Ph) chromosome, is associated with the
development of CML. It consists in a reciprocal translo-
cation occurring in stem cells and progenitors (Michor
2007); part of the BCR (‘‘breakpoint cluster region‘‘) gene
from chromosome 22 is fused with part of the ABL gene on
chromosome 9 (ABL stands for ‘‘Abelson,’’ the name of a
leukemia virus which carries a similar protein). BCR–ABL
fusion gene, which is located on the shorter chromosome
22, activates a number of cell cycle controlling proteins
and tyrosine kinase enzymes, speeding up cell division and
causing genomic instability.
Front line therapy in CML is represented by tyrosine
kinase inhibitors that turn off the signal produced by the Ph
chromosome, limiting the proliferation of BCR–ABL
expressing hematopoietic cells. These inhibitors greatly
reduce the growth of the tumor clone but can cause toxicity
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on full-treated patients (Faber et al. 2006). Moreover,
immature leukemic cells are affected by a chromosomal
instability that brings to a great number of genetic altera-
tions. In particular, point mutations within the protein
tyrosine kinase domain in the BCR–ABL gene itself
(Barthe et al. 2001; Weisberg and Griffin 2001, 2003) are
the basis for the development of acquired resistance to
imatinib-like drugs in a relevant fraction of patients.
A new therapeutic approach, based on the intermittent
dosage of tyrosine kinase inhibitors, has been recently
investigated on clinical studies devoted to the reduction of
hematologic toxicity in patients affected by CML (Faber
et al. 2006; Shah et al. 2008; Martinelli et al. 2009).
These studies have demonstrated that an intermittent
therapy (IT) can be considered a good alternative to the
standard daily dosing in patients with persistent signs of
myelotoxicity, without compromising the patient cytoge-
netic response. Recent clinical studies on the treatment of
hormone-sensitive advanced prostate cancer have dem-
onstrated that the introduction of breaks in long-term
anticancer treatments can prolong tumor response to the
therapy (Seruga and Tannock 2008; Andre´ and Pasquier
2009). Similar results are also reported by Sabnis et al.
(2008) on a breast cancer clinical study. A ‘‘drug-driven
dependency deprivation effect’’ might be able to inhibit
and destroy the most resistant or dependent cancer clones.
In CML context, a temporary interruption of imatinib
therapy was found to significantly reduce the presence of
leukemic cells showing the BCR–ABL Y252H (P-loop)
mutation in a resistant patient (Mu¨ller et al. 2002;
Hochhaus and La Rose´e 2004).
Following these ideas, we like to achieve two goals by
modeling, first reducing drug toxicity during a continuous
imatinib-based treatment, second designing a strategy to
stave off resistance. We have designed a model of leu-
kemic cell evolutionary dynamics for a statistical study of
cancer development in patients treated by an imatinib-like
IT. The aim of this study is to find the optimal therapeutic
approach that minimize imatinib side effects, maximizing
the clinical benefits of this treatment and the quality of
life of the patient. In ‘‘Model of CML evolution’’ section,
we describe the model and give the details of the simu-
lation process. Theoretical results and a comparison with
clinical investigations are reported in ‘‘Results and dis-
cussion’’ section. Conclusions are drawn in ‘‘Conclu-
sions’’ section.
Model of CML evolution
The evolutionary dynamics of cancer initiation and pro-
gression has been theoretically approached with mathe-
matical deterministic equations (Michor et al. 2005, 2006;
Abbott and Michor 2006; Garner et al. 2006) or with sto-
chastic models (Roeder et al. 2006; Brumer et al. 2006;
Iwasa et al. 2004; Michor et al. 2003; Dingli and Michor
2006; Komarova and Wodarz 2007; Zhdanov 2008; Piz-
zolato et al. 2009), both using the basic idea that cancer
arises when a single non-differentiated cell experiences
multiple mutations, as confirmed by numerous studies on
cancer genetics (Knudson 2001; Frank et al. 2003). These
studies describe the temporal evolution of the level of
BCR–ABL positive cells, observed in clinical investiga-
tions on patients treated with imatinib, in terms of a partial
or total failure of the drug efficacy on cancer cells.
We study the evolutionary dynamics of N = 104 repli-
cating cells. This value is several orders of magnitude
lower than the typical total contents of blood cells in
humans, but it is great enough for the statistical study of the
cancer development in a single blood compartment. The
total number of cells is kept constant during the time
evolution, as it can be reasonably assumed for a blood
cancer. In order to simulate the random process of cell
selection for reproduction, mutation, and death, we adopt a
Monte Carlo approach, as already done by several authors
in theoretical cancer studies (see Iwasa et al. 2004; Michor
et al. 2006; Zhdanov 2008; Pizzolato et al. 2009).
In the proposed model, cells are distributed over four
populations: healthy cells (type-0), first-mutated cells
(type-1), double-mutated leukemic cells (type-2), and
resistant leukemic clones (type-3). In a real biological
context, each population of blood cells is composed of the
sum of four sub-populations: stem cells, progenitors, dif-
ferentiated, and terminally differentiated cells. Stem cells
give rise to progenitors, which produce differentiated cells,
which produce terminally differentiated cells. This hierar-
chy applies both to normal and leukemic cells. Because the
blood predominantly contains terminally differentiated
cells, clinical values give an estimate of the fraction of
terminally differentiated leukemic cells (Michor et al.
2005). Therefore, in view of devising a model which
accounts for clinical findings, we consider only the
dynamics of differentiated cells. In this context, the
absence, at a certain time, of differentiated cells belonging
to a given population, e.g., healthy or first-mutated cells,
does not imply their absence at successive times. In fact,
type-0 or type-1 cells can be produced by stem cells of the
same type, which are always present in blood, even if in
low percentage.
In the simulations, where time is measured in units of
cell divisions, we assume that each single time step is long
enough to allow the stem cells to become a differentiated
or a terminally differentiated cells. In the model, we take
into account the presence of stem cells and progenitors
only for what concerns the choice of mutation rates and
fitness of the four simulated populations. In fact, since
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differentiated and terminally differentiated cells can arise
by stem cells, which are characterized by an indefinite
potential for self-renewal (Michor et al. 2005), or by pro-
genitors (Michor 2007), mutation rates and fitness are
considered in the model as averages over these two
sub-populations only. Conversely, death rates can be
considered as averages over the values of all four sub-
populations.
We have scaled the simulation time from cell divisions
to days by using a simulation time step of 0.002 days,
corresponding to 500 cell divisions in one day. This scaling
has been chosen in order to achieve a complete restore of
healthy cells in almost 100 days, as observed in clinical
cases of optimal therapy response (Michor et al. 2005;
Roeder et al. 2006).
The stochastic dynamics of the cancer evolution is
modeled by assuming that cells reproduce asynchronously.
This means that each elementary step of the stochastic
process consists of a birth and a death event, i.e., a Moran
process (Moran 1962). The exact sequence of logical steps
for a single reproduction and death event is described by
the flowcharts shown in Figs. 1 and 2, respectively. For the
birth, one of the N cells is randomly chosen proportionally
to its capacity to reproduce. The fitness of type-0 and type-
1 cells are set equal to 1 as already adopted in other the-
oretical studies (Iwasa et al. 2004; Pizzolato et al. 2009). In
the absence of therapy, the reproductive rate of a leukemic
cell is assumed to be ten times that of a normal cell. This
value is suitable to describe the stochastic dynamics of the
leukemic cells after the disease has reached a ‘‘macro-
scopic‘‘ stage of evolution, while the dormant phase of
CML, characterized by a latency time of about 5–7 years
(Ichimaru et al. 1981; Horn et al. 2008), should be inves-
tigated by using in the model lower fitness values of the
leukemic cells.
The imatinib-based treatment lowers this value only for
those cells which are sensitive to the drug; resistant leu-
kemic cells are unaffected by the therapy and their repro-
ductive capability remains unchanged. In particular, we
have assumed that imatinib reduces the fitness of type-2
leukemic cells to 0.04. Fitness values have been chosen in
order to match the response of type-2 leukemic cells to that
observed in patients treated by an imatinib-based targeted
therapy (Michor et al. 2005; Roeder et al. 2006).
Healthy cells mutate to cells of type-1 (first allele
mutation) at a rate M01 equal to 0.0005; type-1 cells mutate
to type-2, which are leukemic cells sensitive to the therapy,
at a rate M12 equal to 0.002. These values, comparable with
the mutation rates adopted in the models of Refs. Iwasa
et al. (2004); Michor et al. (2005), guarantee a good
agreement between these findings and clinical results. We
performed simulations also for different values of M01 and
M12, finding that only the waiting time before the first
appearance of a leukemic cell is sensitive to these values
Fig. 1 Flowchart of the
reproduction event in a single
time step. FNi (with i = 0,1,2,3)
are the normalized fitness rates;
M01, M12, M23 are mutation
rates for transitions from type-0
to type-1 cells, from type-1 to
type-2 cells, and from type-2 to
type-3 cells, respectively
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and they do not significantly affect the subsequent course
of the disease. Since the tyrosine kinase inhibition by
imatinib induces apoptosis in BCR–ABL expressing cells
(Vigneri and Wang 2001; Belloc et al. 2007), we take into
account this effect by increasing the death rate of type-2
leukemic cells with respect to the other cell populations
during the therapy. We do not consider back mutations and
neglect direct transitions from healthy (type-0) to leukemic
cells (type-2) or to resistant clones (type-3).
For the study of real cases of therapy effects on cancer
evolution, we have supposed that the cell system could
react to the drug administration by activating multiple
genetic changes that cause an enhancement of the mutation
rates from normal to cancerous cells. This assumption is
supported by the clinical evidence that certain mutations
increase the rate at which subsequent mutations occur
(Jackson and Loeb 1998; Loeb et al. 2002). Clinical studies
show an increasing trend in the number of patients devel-
oping resistance to imatinib within two years of treatment,
with the progression of the disease through the chronic,
accelerated and blast crisis phases (Hochhaus and La Rose´e
2004). These phases are characterized by the presence of
an increasing number of immature leukemic cells (myel-
oblasts) in the blood or bone marrow (Sokal et al. 1988).
Therefore, we have assumed in the model that type-2 cells
become resistant type-3 by mutating at a rate M23 which
has not a constant value, but increases with the number N2
of leukemic double-mutated cells (Fig. 3). The theoretical
trend of M23 versus N2 has been extrapolated from the
behavior of the frequency of acquired hematologic resis-
tance as a function of the number of myeloblasts in the
blood, accordingly with the standard definition of CML
phases cited above (Hochhaus and La Rose´e 2004), and
calculated by the equation
M23 ¼ a þ ðb  ð1  eN2=cÞ=dÞ ð1Þ
where a ¼ 2  104, b ¼ 8:5  103, c ¼ 2:5  103, and
d ¼ 4  107 are the best parameters for which the Eq. 1
reproduces the behavior observed in clinical investigations
(Hochhaus and La Rose´e 2004). The mutation rate M23 has
a latency value of 2  104, and it progressively reaches
the double of its value in the presence of an increase of
immature cells N2.
Since the specific chromosomal mutation (or set of
mutations) that causes the cancerous cell to become resis-
tant and insensitive to the therapy can be considered an
evolutionary reaction of the cell against the drug, we
assume that, during the periods of absence of therapy, the
mutation rate M23 is reduced to such very low values that
we reasonable keep it equal to zero.
Fig. 2 Flowchart of the death
event in a single time step.
DNi (with i = 0,1,2,3) are the
normalized death rates
Fig. 3 Mutation rate M23 as a function of the number of leukemic
cells sensitive to the therapy, calculated by Eq. 1. M23 reproduces the
behavior of the frequency of deleterious mutations associated to the
appearance of resistance as a function of disease progression,
observed in clinical investigations Hochhaus and La Rose´e (2004)
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Results and discussion
In this study, we investigate the response to imatinib-based
therapies, characterized by different drug administration
times, in patients where the proportion of malignant cells has
reached almost 99% at the time of diagnosis. Hence, the
initial condition in the simulations is that all the patient
differentiated cells are of leukemic type-2. As discussed in
the previous section, healthy and first-mutated cells partici-
pate to the reproduction process, although their initial value
is set to zero, because stem cells of these two populations,
even if not directly included into the counting of cells, are
always able to generate a new healthy or a first-mutated cell.
In this context, the resistant clone may originate only by a
stochastic process of mutation from the leukemic phenotype.
Type-3 cells acquire the chance to reproduce themselves
only after the first resistant cell is generated.
The standard daily dosage of imatinib for CML patients
is 400 mg/day (Rea et al. 2009). Because this value is
sufficiently high to persist in patient plasma for about 24 h
(Faber et al. 2006), the standard treatment of CML is
achieved with a continuous therapy. In order to lower the
number of leukemic cells as rapidly as possible during the
first 100 days of treatment, patients are simulated to be
treated with imatinib with the standard daily dosage, cor-
responding to a fully continuous modeled therapy.
This choice has been made first to support patient’s
health, and second to reduce the probability of developing
resistance. Resistance is greater when the number of
immature leukemic cells is higher. For the subsequent
300 days, we have simulated three type of pulsed therapies,
with the standard dose administration interrupted by a time
break of 0.4 day (*10 h), 0.6 day (*14 h), and 0.7 day
(*17 h). The evolution of the same system of cells is
shown, for comparison, in the presence of a continuous
treatment for all 400 days.
Individual patient response under continuous therapy
The evolutionary dynamics of healthy and cancerous cells
are first investigated by monitoring the individual patient
response to a continuous therapy, focusing the attention on
the development of resistance. In Fig. 4, we show three
representative cases of patient response in the presence of
acquired resistance. The data points are all sampled every
30 days starting from t = 10 days. The upper panel
describes a patient which initially responds to the therapy
but, unfortunately, develops resistance in the very early
phase of the treatment, even before the complete restora-
tion of healthy cells. In the central and lower panels, we
show the cell evolution of a patient which reaches a
complete response to the therapy almost eradicating the
leukemic phenotype (solid red line). However, since the
number of leukemic type-2 cells is still greater than zero,
after same time delay, a mutation event leads to the birth of
a resistant clone that briefly brings the system of cells to
relapse.
The functional behavior of the number of leukemic cells
with time (solid red lines in Fig. 4), decreasing during the
efficacy phase of the therapy and subsequently increasing
because of the appearance of resistance, has been compared
with the clinical trends reported by Michor et al. (2005). In
particular, we consider the case of a continuous drug
administration therapy and compare, in Fig. 5, the results of
the simulations, i.e., the percentage of leukemic cells, with
the BCR–ABL values as a percentage of the BCR transcript
levels observed in clinical investigations and reported in
Fig. 4 Temporal evolution of cell populations for three representa-
tive patients developing resistance under continuous therapy. Healthy
cells (dashed green line), first-mutated cells (dashed yellow line),
leukemic cells still sensitive to the therapy (dashed red line), and
resistant leukemic clones (dashed blue line). Continuous green line is
referred to the sum of healthy and type-1 cells and a continuous red
line is used for the sum of type-2 and resistant cells. (Color figure
online)
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Michor et al. (2005). Specifically, the simulated data
decrease with a trend which is in a good agreement with the
time behavior of the BCR–ABL/BCR percentage observed
in clinical data, with a reduction of both simulated and
clinical percentages around 1% within the first 100 days of
therapy. This finding validates the model and justifies the
choice of treating the simulated patients by a continuous
drug administration therapy during the first 100 days.
Resistance start up during IT and average cell evolution
The occurrence of a genetic alteration that leads a leukemic
cell to become resistant to the therapy is a stochastic pro-
cess. Hence, in order to give a statistical significance to the
descriptions, we have repeated every simulation 5  103
times.
First of all, we have estimated the mean waiting time for
the development of resistance and the average increasing
trend in the number of resistant cells. The mean waiting
time before the first appearance of a resistant clone has been
calculated by averaging over all simulated patients that
have developed resistance within 400 days. However, the
number nc of resistant patients under continuous therapy is
greater than the number mi (the index i refers to different
ITs) observed during the three cases of IT. Hence, we have
normalized the samples of resistant patients under IT by
assuming that among all patients which have not developed
resistance under intermittent treatment, nc-mi will acquire
resistance at the 400th day. In this way, the mean waiting
time is calculated by averaging over the same number of
patients. For every therapeutic approach, the average
increasing trend of resistant cells with time has been
determined by firstly shifting all resistant patient trends in a
way that each single starting point coincided with the mean
waiting time and, after that, we have calculated the average
number of type-3 cells on equivalent times.
In Fig. 6 we show that, by adopting an IT instead of the
continuous one, an evident time delay into the appearance
of resistance can be obtained. In particular, the best result
in terms of a longer waiting time is achieved with the
standard daily dosage alternative with a break of 0.4 day
(see the inset of Fig. 6). Except for the starting time of
resistance, the average progression trend of resistant cells
does not show significant differences between the cases of
IT and that of continuous therapy.
In Fig. 7, we show the temporal evolution of the number
of healthy and first-mutated cells (green lines), cancerous
cells still sensitive to the therapy (red lines) and resistant
clones (blue lines), averaged over the whole set of simu-
lated patients. A full continuous therapy throughout all 400
days is described by solid lines. The evolution of the same
system of cells is shown, after 100 days of continuous
treatment, in the presence of an IT characterized by the
same dose duration and three different values of breaks.
Of course the best results, in terms of a permanent dis-
appearance of the leukemic type-2 cells, is achieved with a
continuous therapy. However, the results shown in Fig. 7
demonstrate that an IT could also represent a valid choice in
patients with high risk of toxicity. In fact, even if an
increase of the average number of leukemic cells sensitive
Fig. 5 Temporal evolution of the percentage of leukemic cells for the
first 200 days of treatment characterized by a continuous drug
administration. Red dots connected by the red line represent the
percentage of modeled cancerous cells averaged over all those
simulated patients who did not develop resistance during the first year
of therapy. For comparison, we also plot the median with quartiles
(blue squares and bars) of the BCR–ABL values expressed as a
percentage of the BCR transcript levels taken over real patients who
do not have a rise in the leukemic cell burden during the first
12 months of therapy (data published in Michor et al. (2005)). (Color
figure online)
Fig. 6 Average trend of resistance development under continuous
therapy (solid line) and IT with breaks of 0.4, 0.6, and 0.7 days
(dotted, dashed, and dotted–dashed lines). The mean waiting time
before the first appearance of a resistant type-3 cell is calculated by
averaging over all patients developing resistance. The average
increasing trend of resistant cells is determined by scaling all the
resistant patient trends with respect to the mean waiting time and
calculating the average number of type-3 cells on equivalent times.
The inset shows the mean waiting time for patients developing
resistance under the three modeled ITs, characterized by different
therapy interruptions, with respect to that expected under continuous
therapy
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to the therapy (red lines) is observed during an IT, this effect
is partially counterbalanced by a reduction on the average
number of resistant cells. In the best case, the IT with breaks
of 0.4 days reduces the average number of resistant cells
without causing a significant increase on the number of
leukemic type-2 cells (in Fig. 7 the dotted red line is almost
coincident with the continuous one). When larger time
windows between two consecutive doses become neces-
sary, the average number of cancerous cells starts to
increase again, suggesting a change of therapeutic strategy.
The observed reduction on the average number of
resistant cells during IT with breaks of 0.4 days is essen-
tially due to a lower number of patients developing resis-
tance. In Fig. 8 we show the percentage of patients
developing resistance as a function of time, following the
aforementioned therapeutic strategies. The statistical error
associated to these values, calculated by repeating the set
of simulations for 10 times, is less than 0.5%. We find an
advantage of the IT with breaks of 0.4 days over the con-
tinuous therapy approach for the whole duration of
400 days. IT characterized by therapy breaks of 0.6 days
shows a comparable improvement in terms of a reduction
in the percentage of patients developing resistance, while
IT with breaks of 0.7 days, after an initial positive
response, shows a worsening, becoming essentially
equivalent to the continuous case.
Conclusions
Recent clinical oncology investigations indicate that an IT
reduces both the incidence of toxicity and the complica-
tions that arise from the side effects due to a long-term
continuous treatment with imatinib. In this study, by using
a computational model, we have compared the effects of an
intermittent imatinib-based therapy on the evolutionary
dynamics of normal and cancerous cells in patients affected
by CML, with respect to the standard treatment achieved
by the continuous drug administration. Specifically, we find
a good agreement between the theoretical results (Fig. 5)
and those obtained in clinical investigations (Michor et al.
2005). With the aim of finding a less aggressive but still
effective therapy, we have simulated the evolutionary
dynamics of healthy and leukemic cells of 5000 patients in
the presence of three type of pulsed therapies with the
standard daily dose administration delayed by different
time lags.
We have found that an IT can represent a valid alter-
native in patients with high risk of toxicity, without com-
promising the chances of a sustained tumor suppression.
For therapy breaks until 0.6 day, the presence of a slight
increase on the average number of leukemic cells is par-
tially counterbalanced by a reduction on the average
number of resistant clones. Furthermore, we have shown
that an IT with a daily dosage retarded by a break of
0.4 day results into a more effective alternative with
respect to a continuous therapy.
An IT with a break of 0.4 day reduces the percentage of
patients developing resistance to the drug after 400 day of
treatment of about 5%. Hence, the introduction of breaks in
anti-cancer therapy could prevent the treatment failure due
to the developing of drug resistance. At last, but not least,
all ITs show an appreciable time delay in the resistance
switching on, with respect to the case of a continuous
therapy.
Going behind the numerical details of the simulations,
these findings show that an IT, appropriately tuned on
Fig. 7 Temporal evolution of cell populations: Healthy and first-
mutated cells (green lines), leukemic cells still sensitive to the therapy
(red lines), and resistant leukemic clones (blue lines). These values of
the number of cells represent averages over 5000 simulated patients.
Continuous lines are referred to the continuous therapy. Dotted,
dashed, and dotted–dashed lines show the dynamics of the system of
cells in the presence of an IT with breaks of 0.4, 0.6, and 0.7 days,
respectively. The dotted red line is almost coincident with the red
continuous one. (Color figure online)
Fig. 8 Percentage of patients developing resistance as a function of
time. Solid line represents the case of a continuous therapy. Dotted,
dashed, and dotted–dashed lines represent an IT with breaks of 0.4,
0.6, and 0.7 days, respectively
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specific patient necessities, should be preferred to the
continuous one. The introduction of short breaks in long-
term imatinib-based therapies can potentially enhance the
treatment efficacy and considerably improve the quality of
life of CML patients.
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